The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Releases Biosimilar Guidance, Medicare Will Cover Infliximab-dyyb & More

FDA Releases Biosimilar Guidance, Medicare Will Cover Infliximab-dyyb & More

January 18, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

FDA Biosimilar Guidance for Industry
On Dec. 28, 2016, pharmaceutical manufacturers received U.S. Food and Drug Administration (FDA) guidance on developing clinical pharmacology programs to support biosimilar development and approval.1,2 The document is meant to assist manufacturers in proving they have created a new drug that can be used in the same way as its reference product. Drug industry stakeholders have been paying close attention to FDA guidance on biosimilars to enhance their ability to get FDA approval for alternatives to existing biologics.

You Might Also Like
  • Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States
  • Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
Also By This Author
  • Brodalumab Approved for Plaque Psoriasis

This finalizes the draft guidance issued by the FDA in May 2014.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Medicare Will Cover Infliximab-dyyb
The biosimilar infliximab-dyyb (Inflectra) was FDA approved on April 5, 2016.3 As of Jan. 1, 2017, the Centers for Medicare and Medicaid Services (CMS) will begin paying for infliximab-dyyb for Medicare enrollees.4 According to the manufacturer, Pfizer, payment will be as a Medicare Part B-covered drug at 15% less than the wholesale acquisition cost of the original formulation of infliximab (Remicade), the reference product. The wholesale acquisition cost does not include discounts to providers, payers and other groups involved in purchasing.

Pfizer has developed the enCompass program, which is a comprehensive reimbursement service and patient support program. It offers coding and reimbursement assistance for providers, co-pay assistance for eligible patients with commercial insurance that covers infliximab-dyyb and financial assistance for eligible uninsured and underinsured patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Janssen Submits Golimumab for New Uses
Two Supplemental Biologics License Applications (sBLAs) have been submitted to the FDA for golimumab (Simponi Aria), a fully human anti-tumor necrosis factor (TNF)-alpha therapy currently approved as a 30-minute intravenous (IV) infusion for treating adult patients with moderate to severe active rheumatoid arthritis (RA) with methotrexate.5 The manufacturer, Janssen Biotech, is trying to obtain approval for golimumab to treat adults with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

Data from two different Phase 3 studies, GO-ALIVE (in adults with active AS) and GO-VIBRANT (in adults with active PsA), were used for the sBLA submission. In both studies, the safety and efficacy of golimumab were demonstrated at a dosage of 2 mg/kg IV infusions given every eight weeks, after two starter doses at Weeks 0 and 4.

Data from the GO-ALIVE study were presented at the 2016 ACR/ARHP Annual Meeting in Washington, D.C.6 GO-VIBRANT study results will be presented at a future scientific conference.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Ruoff A. FDA completes guidance on developing biosimilars. Bloomberg. 2016 Dec 29.
  2. U.S. Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product: Guidance for industry. 2016 Dec 28.
  3. U.S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. 2016 April 5.
  4. Walsh N. Medicare to cover infliximab biosimilar: Cost to system is 15% lower than original Remicade. MedpageToday. 2017 Jan 6.
  5. Janssen Pharmaceutical Co. News release: Janssen submits two applications to FDA seeking approval of Simponi Aria (golimumab) for the treatment of active psoriatic arthritis and active ankylosing spondylitis. 2017 Dec 20.
  6. Deodhar AA, Reveille JD, Harrison DD, et al. Safety and efficacy of intravenous golimumab in adult patients with active ankylosing spondylitis: Results through Week 28 [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).

Pages: 1 2 | Multi-Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, Centers for Medicare and Medicaid Services (CMS), FDA, Food and Drug Administration, Golimumab, infliximab-dyyb, Medicare

You Might Also Like:
  • Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States
  • Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
  • Infliximab Biosimilar Receives FDA Approval

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)